Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Inclusion Criteria: 1. Age ≥ 18 years old 2. Stable coronary artery disease on stable medical treatment. 3. BMI equal to or less than 30 kg/m2 4. No clinically significant abnormalities in baseline laboratory work 5. No clinically significant arrhythmias on baseline 12-lead electrocardiogram 6. Female subjects must be post-menopausal, surgically sterilized or have negative urine beta human chorionic gonadotropin pregnancy test at initial screening and maintain effective contraceptive methods throughout the trial and for 7 days following the end of dosing treatment. Exclusion Criteria: 1. Any contraindication against the use of clopidogrel, ticagrelor and/or ASA. 2. Oral anticoagulation therapy. 3. History of intracranial bleeding. 4. Recent or active pathological bleeding, such as peptic ulcer. 5. Moderate or severe hepatic impairment. 6. History or risk of bradycardia. 7. Known second- or third-degree AV block without pacemaker 8. Dyspnea (NYHA III/IV), wheezing asthma or COPD. 9. Coronary artery bypass graft (CABG) surgery within 90 days prior to screening or at any time after consent. 10. Percutaneous coronary intervention (PCI) within 90 days prior to screening or at any time following consent. 11. Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent. 12. Any scheduled surgery during the trial period, including dental. 13. Concomitant therapy with strong cytochrome CYP 3A inhibitor or inducer. 14. Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox) 15. Known hypersensitivity to the investigational drug or any of its components. 16. Known hypersensitivity to adenosine. 17. Lactose intolerance 18. Breastfeeding or pregnancy. 19. Claustrophobia or inability to lie still in a supine position 20. Unwillingness to provide informed consent